Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 10/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353709 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL392505 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL12291433 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL356202 | 1.00 | DPP4 (1.00) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708932 | 0.98 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5708931 | 0.98 | DPP4 (0.97) | DPP4DPP7DPP8DPP9 | |
| Fumaric Acid SCHEMBL29353244 | 0.92 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 | |
| Fumaric Acid SCHEMBL21638348 | 0.92 | DPP4 (0.84) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071368 | 0.90 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL28071366 | 0.90 | DPP4 (0.82) | DPP4DPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140287040-A1 | Formulation | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140205663-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20140205663-A1 | Direct Compression Formulation and Process | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20130052239-A1 | Formulation | JOSHI YATINDRA (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | KOWALSKI JAMES (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | BALKAN BOERK (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143217-B2 | Use of DPP-IV inhibitor to reduce hypoglycemic events | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | PFEFFER SABINE (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20110245317-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-10-06 | — | — | US | disclosed |
| US-20110236479-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20080269311-A1 | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors | VILLHAUER EDWIN BERNARD | 2008-10-30 | — | — | US | disclosed |
| US-20080227825-A1 | Dipeptidylpeptidase IV inhibitors such as vildagliptin and metformin; tablets | JOSHI YATINDRA | 2008-09-18 | — | — | US | disclosed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | disclosed |
| US-20080200510-A1 | Combination of Organic Compounds | MILOSAVLJEVIC-RISTIC SMILJANA | 2008-08-21 | — | — | US | disclosed |
| US-20080193529-A1 | Direct Compression Formulation and Process | KOWALSKI JAMES | 2008-08-14 | — | — | US | disclosed |
| US-20080070922-A1 | Combination of Organic Compounds | BURKEY BRYAN | 2008-03-20 | — | — | US | disclosed |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | KOWALSKI JAMES | 2008-02-14 | — | — | US | disclosed |
| WO-2007127204-A2 | METHODS AND COMPOSITIONS RELATING TO IMMUNOSTIMULATION | DARA BIOSCIENCES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254944-A1 | Use of Organic Compounds | NOVARTIS AG (CH) | 2007-11-01 | — | — | US | disclosed |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | HOLMES DAVID G | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070922-A1 | Combination of Organic Compounds | GIPR, IRS1, IGF1R | DPP4 14/4885DPP7 100/4885DPP8 93/4885 |
| US-20070149451-A1 | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | GIPR, DPP4, MC4R | DPP4 2/4885DPP7 9/4885DPP8 20/4885 |
| US-20080038341-A1 | Free-flowing, cohesive tableting powder for direct compressed tablet; DPP-IV inhibitor and glitazone, in unit dosage form; acceptable dissolution profile; acceptable degrees of hardness, resistance to chipping, short disintegration time | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120015029-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 6/4885 |
| US-20110236479-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20080200510-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP9 | DPP4 1/4885DPP7 5/4885DPP8 4/4885 |
| US-20080193529-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20080227825-A1 | Dipeptidylpeptidase IV inhibitors such as vildagliptin and metformin; tablets | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20140205663-A1 | Direct Compression Formulation and Process | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20070254944-A1 | Use of Organic Compounds | DPP4, DPP8, DPP3 | DPP4 1/4885DPP7 4/4885DPP8 2/4885 |
| US-20140287040-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20080269311-A1 | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors | HTR4, DPP4, HTR3B | DPP4 2/4885DPP7 20/4885DPP8 23/4885 |
| US-20130052239-A1 | Formulation | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 4/4885 |
| US-20120294939-A1 | DIRECT COMPRESSION FORMULATION AND PROCESS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20120149639-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 5/4885 |
| US-20110245317-A1 | USE OF ORGANIC COMPOUNDS | DPP4, DPP8, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.